RU2015125699A - Антигены и комбинации антигенов pseudomonas - Google Patents
Антигены и комбинации антигенов pseudomonas Download PDFInfo
- Publication number
- RU2015125699A RU2015125699A RU2015125699A RU2015125699A RU2015125699A RU 2015125699 A RU2015125699 A RU 2015125699A RU 2015125699 A RU2015125699 A RU 2015125699A RU 2015125699 A RU2015125699 A RU 2015125699A RU 2015125699 A RU2015125699 A RU 2015125699A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- antigens
- composition
- pse53
- pse21
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (22)
1. Иммуногенная композиция, включающая один или более антигенов, выбранных из перечня: антигена PSE54 (PA5340); антигена PSE44-4 (PA3526); антигена PSE10-1 (PA1178); антигена PSE21-5 (PA5112); антигена PSE27-1 (PA0328); антигена PSE52-1 (PA4765); антигена PSE53-1 (PA5047); антигена PSE11-3 (PA1248); антигена PSE41-5 (PA2407); PSE47A-2 (PA4082); PSE5-1 (PA0595); PSE13-2 (PA1954); PSE17-1 (PA3692); PSE18-2 (PA4370); PSE20-1 (PA4735); PSE23-1 (PA3647); PSE24-1 (PA0126); PSE25-1 (PA0189); PSE26-1 (PA0274); PSE28-2 (PA0537); PSE31- 2 (PA0737); PSE33-2 (PA1086); PSE42-1 (PA2793); PSE45-2 (PA3535); PSE50-1 (PA4578); PSE51-4 (PA4667); PSE19-1 (PA4710); PSE34-1 (PA1106); PSE36-3 (PA1324); PSE38-1 (PA1777).
2. Иммуногенная композиция по п. 1, в которой антигены выбраны из любого из антигена PSE54 (PA5340); антигена PSE44-4 (PA3526); антигена PSE21-5 (PA5112); антигена PSE27-1 (PA0328); антигена PSE53-1 (PA5047); антигена PSE41-5 (PA2407); PSE47A-2 (PA4082); PSE5-1 (PA0595); PSE13-2 (PA1954); PSE17-1 (PA3692); PSE18-2 (PA4370); PSE20-1 (PA4735); PSE23-1 (PA3647); PSE24-1 (PA0126); PSE25-1 (PA0189); PSE26-1 (PA0274); PSE28-2 (PA0537); PSE31-2 (PA0737); PSE33-2 (PA1086); PSE42-1 (PA2793); PSE45-2 (PA3535); PSE50-1 (PA4578); PSE51-4 (PA4667); PSE34-1 (PA1106); PSE36-3 (PA1324).
3. Композиция по п. 1, в которой один или более антигенов выбраны из антигена PSE 54 (PA5340), антигена PSE21-5 (PA5112); антигена PSE27-1 (PA0328); PSE41-5 (PA2407); антигена PSE44-4 (PA3526); антигена PSE47A-2 (PA4082); антигена PSE53-1 (PA5047), или антигена PSE52-1 (PA4765); антигена PSEl0-1 (PA1178); PSE11-3 (PA1248).
4. Композиция по п. 1, включающая по меньшей мере два антигена в комбинации, выбранных из перечня: антигена PSE54 (PA5340); антигена PSE44-4 (PA3526); антигена PSE10-1 (PA1178); антигена PSE21-5 (PA5112); антигена PSE27-1 (PA0328); антигена PSE52-1 (PA4765); антигена PSE53-1 (PA5047); антигена PSE11-3 (PA1248); антигена PSE41 (PA2407); PSE47A-2 (PA4082); PSE5-1(PA0595); PSE13-2 (PA1954); PSE17-1 (PA3692); PSE18-2 (PA4370); PSE20-1 (PA4735); PSE23-1 (PA3647); PSE24-1 (PA0126); PSE25-1 (PA0189); PSE26-1 (PA0274); PSE28-2 (PA0537); PSE31-2 (PA0737); PSE33-2 (PA1086); PSE42-1 (PA2793); PSE45-2 (PA3535); PSE50-1 (PA4578); PSE51-4 (PA4667); PSE19-1 (PA4710); PSE34-1 (PA1 106); PSE36-3 (PA1324); PSE38-1 (PA1777).
5. Композиция по п. 4, дополнительно включающая любые другие антигены, выбранные из перечня: PilA, OprF-OprI, FliC, FLiD, ExoA, и где один из антигенов представляет собой PSE 54.
6. Композиция по п. 4, включающая по меньшей мере один антиген, выбранный из PSEl0-1 (PA1178), PSE52-1 (PA4765), PSE53-1 (PA5047), PSE21-5 (PA4765), и в которой другой антиген представляет собой PSE54 (PA5340).
7. Композиция по п. 4, включающая два или более антигенов, выбранных из группы, состоящей из антигена PSE54 (PA5340); антигена PSE10-1 (PA1178); антигена PSE44-4 (PA3526); антигена PSE52-1 (PA4765); антигена PSE53-1 (PA5047); антигена PSE21-5 (PA5112); антигена PSE27-1 (PA0328); антигена PSE47A-2 (PA4082) или OprF-OprI.
8. Композиция по п. 7, где один или более из указанных антигенов адсорбирован на адъюванте на основе гидроксида алюминия, и необязательно где композиция включает гистидиновый буфер.
9. Композиция по п. 8, дополнительно включающая один или более конъюгатов (i) экзополисахарида P. aeruginosa и (ii) белок-носитель.
10. Иммуногенная композиция, включающая полипептид по любому из пп. 1-9 и дополнительно включающая одно или более из:
(А) одного или более конъюгатов (i) экзополисахарида S. aureus;
(В) одного или более белковых антигенов (i) S. aureus или
(С) одного или более патогенных антигенов E. coli;
(D) одного или более патогенных антигенов B. Cenocepacia.
11. Иммуногенная композиция, включающая полипептид по любому из п. 1 или 2, и один или более из (i) антигена OprF-OprI; (ii) антигена FliC; (iii) антигена FliD и/или (iv) антигена PilA.
12. Композиция по п. 10, включающая адъювант.
13. Полипептид, включающий аминокислотную последовательность, идентичную на 80% или более аминокислотной последовательности, выбранной из любой из SEQ ID NOs: 1-35 или SEQ ID NOs: 36-65.
14. Фармацевтическая композиция, включающая полипептид по любому из пп. 11, 12 или 13.
15. Иммуногенная композиция по п. 10 для применения в индукции иммунного ответа у млекопитающего.
16. Иммуногенная композиция по п. 10 для применения в качестве профилактической или терапевтической вакцины против внутрибольничных инфекций.
17. Способ индукции иммунного ответа у млекопитающего, включающий стадию введения млекопитающему эффективного количества полипептида или композиции по любому из пп. 1-16.
18. Композиция по п. 11, включающая адъювант.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201221638 | 2012-11-30 | ||
GB1221638.8 | 2012-11-30 | ||
PCT/EP2013/074864 WO2014083060A2 (en) | 2012-11-30 | 2013-11-27 | Pseudomonas antigens and antigen combinations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018137673A Division RU2018137673A (ru) | 2012-11-30 | 2013-11-27 | Антигены и комбинации антигенов pseudomonas |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015125699A true RU2015125699A (ru) | 2017-01-11 |
Family
ID=49681020
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015125699A RU2015125699A (ru) | 2012-11-30 | 2013-11-27 | Антигены и комбинации антигенов pseudomonas |
RU2018137673A RU2018137673A (ru) | 2012-11-30 | 2013-11-27 | Антигены и комбинации антигенов pseudomonas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018137673A RU2018137673A (ru) | 2012-11-30 | 2013-11-27 | Антигены и комбинации антигенов pseudomonas |
Country Status (24)
Country | Link |
---|---|
US (3) | US9987344B2 (ru) |
EP (2) | EP2925355B1 (ru) |
JP (2) | JP6340011B2 (ru) |
KR (1) | KR20150100665A (ru) |
CN (2) | CN111249455A (ru) |
AU (2) | AU2013351182C1 (ru) |
BR (1) | BR112015012762A2 (ru) |
CA (1) | CA2892688A1 (ru) |
CY (1) | CY1119912T1 (ru) |
DK (1) | DK2925355T3 (ru) |
ES (2) | ES2826555T3 (ru) |
HR (1) | HRP20180039T1 (ru) |
HU (1) | HUE036158T2 (ru) |
IL (2) | IL238987B (ru) |
LT (1) | LT2925355T (ru) |
MX (2) | MX366876B (ru) |
NO (1) | NO2925355T3 (ru) |
PL (1) | PL2925355T3 (ru) |
PT (1) | PT2925355T (ru) |
RS (1) | RS56886B1 (ru) |
RU (2) | RU2015125699A (ru) |
SG (2) | SG10201706671WA (ru) |
SI (1) | SI2925355T1 (ru) |
WO (1) | WO2014083060A2 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5893640B2 (ja) * | 2010-12-23 | 2016-03-23 | ファルネファ オーストリア ゲーエムベーハー | Oprf/i試薬と入院および他の患者におけるその利用 |
EP4116316A1 (en) * | 2015-07-04 | 2023-01-11 | Evaxion Biotech A/S | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa |
CN105732778A (zh) * | 2016-03-02 | 2016-07-06 | 中国人民解放军第三军医大学 | 铜绿假单胞菌重组蛋白OprL及制备方法和应用 |
CN110922455B (zh) * | 2019-12-28 | 2023-01-13 | 重庆艾力彼生物科技有限公司 | 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
DE3718591A1 (de) | 1987-06-03 | 1988-12-15 | Behringwerke Ag | Aeusseres membranprotein f von pseudomonas aeruginosa |
US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
CA2063271A1 (en) | 1989-07-14 | 1991-01-15 | Subramonia Pillai | Cytokine and hormone carriers for conjugate vaccines |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
HU222247B1 (hu) | 1991-03-01 | 2003-05-28 | Minnesota Mining And Manufacturing Company | 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható 1H-imidazo[4,5-c]kinolin-5N-oxid-származékok |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ES2328424T3 (es) | 1993-09-15 | 2009-11-12 | Novartis Vaccines And Diagnostics, Inc. | Vectores de alfavirus recombinantes. |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
DE69515613T2 (de) | 1994-12-16 | 2000-11-30 | Chiron Behring Gmbh & Co | Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa |
UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
KR100585408B1 (ko) | 1998-02-12 | 2006-06-01 | 와이어쓰 홀딩스 코포레이션 | 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신 |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
KR20010042573A (ko) | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
ES2296390T3 (es) | 1998-05-07 | 2008-04-16 | Corixa Corporation | Composicion coadyuvante y procedimiento para su uso. |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
JP2004505885A (ja) | 1998-08-19 | 2004-02-26 | ノース アメリカン ワクチン, インコーポレイテッド | N−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体 |
AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AU2753100A (en) | 1999-02-03 | 2000-08-25 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
CN1391483A (zh) | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
DE60022665T2 (de) | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
US6551759B2 (en) | 2000-06-13 | 2003-04-22 | Agfa-Gevaert | Direct-to-plate flexographic printing plate precursor |
WO2002022598A1 (en) | 2000-09-11 | 2002-03-21 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
KR100718371B1 (ko) | 2001-11-27 | 2007-05-14 | 애나디스 파마슈티칼스, 인코포레이티드 | 3-β-D-리보푸라노실티아졸로[4,5-d]피리디민누클레오시드 및 이의 용도 |
EP1499311B1 (en) | 2002-03-29 | 2009-11-04 | Novartis Vaccines and Diagnostics, Inc. | Substituted benzazoles and use thereof as raf kinase inhibitors |
ATE477251T1 (de) | 2002-08-23 | 2010-08-15 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
CA2511646A1 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
EP1594524B1 (en) | 2003-01-21 | 2012-08-15 | Novartis Vaccines and Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
JP5393978B2 (ja) | 2004-04-05 | 2014-01-22 | ゾエティス・ピー・エルエルシー | マイクロ流動化された水中油型乳剤及びワクチン組成物 |
US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US9931397B2 (en) | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
BRPI0717219B8 (pt) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
JP2008133206A (ja) | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
CA2691626A1 (en) | 2007-06-29 | 2009-01-08 | Jiro Tanaka | Pseudomonas aeruginosa-outer membrane protein pa4710 |
WO2010107778A1 (en) | 2009-03-18 | 2010-09-23 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
JP5893640B2 (ja) | 2010-12-23 | 2016-03-23 | ファルネファ オーストリア ゲーエムベーハー | Oprf/i試薬と入院および他の患者におけるその利用 |
-
2013
- 2013-11-27 PL PL13798638T patent/PL2925355T3/pl unknown
- 2013-11-27 US US14/648,198 patent/US9987344B2/en not_active Expired - Fee Related
- 2013-11-27 PT PT137986386T patent/PT2925355T/pt unknown
- 2013-11-27 ES ES17201384T patent/ES2826555T3/es active Active
- 2013-11-27 SG SG10201706671WA patent/SG10201706671WA/en unknown
- 2013-11-27 BR BR112015012762A patent/BR112015012762A2/pt not_active IP Right Cessation
- 2013-11-27 CA CA2892688A patent/CA2892688A1/en not_active Abandoned
- 2013-11-27 NO NO13798638A patent/NO2925355T3/no unknown
- 2013-11-27 RU RU2015125699A patent/RU2015125699A/ru unknown
- 2013-11-27 CN CN202010073358.2A patent/CN111249455A/zh active Pending
- 2013-11-27 HU HUE13798638A patent/HUE036158T2/hu unknown
- 2013-11-27 ES ES13798638.6T patent/ES2656510T3/es active Active
- 2013-11-27 EP EP13798638.6A patent/EP2925355B1/en active Active
- 2013-11-27 AU AU2013351182A patent/AU2013351182C1/en not_active Ceased
- 2013-11-27 DK DK13798638.6T patent/DK2925355T3/en active
- 2013-11-27 SG SG11201504258RA patent/SG11201504258RA/en unknown
- 2013-11-27 SI SI201330857T patent/SI2925355T1/en unknown
- 2013-11-27 MX MX2015006791A patent/MX366876B/es active IP Right Grant
- 2013-11-27 KR KR1020157016029A patent/KR20150100665A/ko not_active Application Discontinuation
- 2013-11-27 RU RU2018137673A patent/RU2018137673A/ru not_active Application Discontinuation
- 2013-11-27 CN CN201380071425.5A patent/CN105142666A/zh active Pending
- 2013-11-27 RS RS20180023A patent/RS56886B1/sr unknown
- 2013-11-27 JP JP2015544454A patent/JP6340011B2/ja not_active Expired - Fee Related
- 2013-11-27 LT LTEP13798638.6T patent/LT2925355T/lt unknown
- 2013-11-27 EP EP17201384.9A patent/EP3345617B1/en active Active
- 2013-11-27 WO PCT/EP2013/074864 patent/WO2014083060A2/en active Application Filing
-
2015
- 2015-05-25 IL IL238987A patent/IL238987B/en active IP Right Grant
- 2015-05-28 MX MX2019008779A patent/MX2019008779A/es unknown
-
2018
- 2018-01-09 HR HRP20180039TT patent/HRP20180039T1/hr unknown
- 2018-02-13 CY CY20181100174T patent/CY1119912T1/el unknown
- 2018-05-11 JP JP2018092145A patent/JP2018135388A/ja active Pending
- 2018-05-11 US US15/977,901 patent/US20180256701A1/en not_active Abandoned
- 2018-05-31 AU AU2018203852A patent/AU2018203852B2/en not_active Ceased
-
2019
- 2019-06-26 IL IL267657A patent/IL267657A/en unknown
-
2020
- 2020-08-07 US US16/988,001 patent/US20200360504A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
JP2012523246A5 (ru) | ||
RU2016111934A (ru) | Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы | |
RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
EA201001212A1 (ru) | Лечение микробных инфекций | |
MX2018002340A (es) | Metodos y composiciones para proteccion inmunitaria contra e. coli patogena extraintestinal. | |
JP2011250797A5 (ru) | ||
BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
EP3156070A3 (en) | Newcastle disease virus vectored herpesvirus vaccines | |
EA201891124A3 (ru) | Новые мукозные адъюванты и системы доставки | |
RU2015125699A (ru) | Антигены и комбинации антигенов pseudomonas | |
JP2015529678A5 (ru) | ||
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
MA32388B1 (fr) | Immunomodulation par des inhibiteurs d'iap | |
RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
JP2013501007A5 (ru) | ||
EP2762153A3 (en) | Vaccine composition for mucosal administration | |
RU2014106936A (ru) | Самосборные пептидные наночастицы в качестве вакцин против норовирусной инфекции | |
DK3016673T3 (da) | Pattedyrsmælkeosteopontin til forbedring af immunreaktion | |
WO2015144732A3 (en) | Uses of parasite macrophage migration inhibitory factors | |
RU2015113230A (ru) | Домен CNAB SDRE STAPHYLOCOCCUS AUREUS и его применение для вакцинации |